| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
49,450,000 |
| Market
Cap: |
1.52(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$25.5 - $42.47 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 623 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
119,323 |
119,323 |
189,781 |
290,198 |
| Total Sell Value |
$3,656,226 |
$3,656,226 |
$6,334,261 |
$12,063,571 |
| Total People Sold |
1 |
1 |
15 |
16 |
| Total Sell Transactions |
3 |
3 |
34 |
58 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Stack David M |
CEO and Chairman |
• • – |
2019-06-11 |
4 |
OE |
$1.61 |
$73,560 |
D/D |
24,000 |
169,231 |
|
- |
|
| Riker Lauren Bullaro |
Vice President, Finance |
• – – |
2019-06-10 |
4 |
S |
$44.28 |
$94,139 |
D/D |
(2,126) |
10,042 |
|
- |
|
| Dunker Kristen Marie |
CAO and General Counsel |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,600 |
25,445 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
6,881 |
|
- |
|
| Greenstreet Yvonne |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
9,761 |
|
- |
|
| Pace Gary W |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
36,953 |
|
- |
|
| Scranton Richard |
Chief Scientific Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
16,061 |
|
- |
|
| Scranton Richard |
Chief Scientific Officer |
• – – |
2019-06-05 |
4 |
AS |
$43.50 |
$178,959 |
D/D |
(4,114) |
11,061 |
|
- |
|
| Brege Laura |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
8,761 |
|
- |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,400 |
16,336 |
|
- |
|
| Winston Roy |
Chief Clinical Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,600 |
22,139 |
|
- |
|
| Longenecker John P Phd |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
10,061 |
|
- |
|
| Kronenfeld Mark A. |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
14,411 |
|
- |
|
| Mcloughlin Dennis |
Chief Commercial Officer |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,600 |
19,422 |
|
- |
|
| Laranjeira Charles Anthony |
SVP, Technical Operations |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
10,367 |
|
- |
|
| Froimson Mark |
Director |
– • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
4,134 |
5,016 |
|
- |
|
| Stack David M |
CEO and Chairman |
• • – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
23,700 |
145,231 |
|
- |
|
| Riker Lauren Bullaro |
Vice President, Finance |
• – – |
2019-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
12,168 |
|
- |
|
| Dunker Kristen Marie |
CAO and General Counsel |
• – – |
2019-06-04 |
4 |
S |
$42.91 |
$108,519 |
D/D |
(2,529) |
19,845 |
|
- |
|
| Hastings Paul J |
Director |
– • – |
2019-06-04 |
4 |
AS |
$42.66 |
$33,360 |
D/D |
(782) |
2,747 |
|
- |
|
| Scranton Richard |
Chief Scientific Officer |
• – – |
2019-06-04 |
4 |
AS |
$42.66 |
$210,662 |
D/D |
(4,926) |
15,175 |
|
- |
|
| Reinhart Charles A. Iii |
Chief Financial Officer |
• – – |
2019-06-04 |
4 |
S |
$42.91 |
$47,458 |
D/D |
(1,106) |
11,936 |
|
- |
|
| Winston Roy |
Chief Clinical Officer |
• – – |
2019-06-04 |
4 |
S |
$42.91 |
$30,981 |
D/D |
(722) |
16,539 |
|
- |
|
| Mcloughlin Dennis |
Chief Commercial Officer |
• – – |
2019-06-04 |
4 |
S |
$42.91 |
$47,158 |
D/D |
(1,099) |
13,822 |
|
- |
|
| Laranjeira Charles Anthony |
SVP, Technical Operations |
• – – |
2019-06-04 |
4 |
S |
$42.91 |
$18,451 |
D/D |
(430) |
5,367 |
|
- |
|
781 Records found
|
|
Page 14 of 32 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.44 (1.45%) 
